Clinical Trial Update: Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/2 dose-escalation trial of entinostat with pembrolizumab in non-small cell lung cancer, with expansion cohorts in melanoma and colorectal cancer, has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Entinostat (MS-275) (entinostat)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer, Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-03-20